General Info

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company based in Lexington, Mass. It creates medicines through a scientific approach utilizing the naturally occurring element deuterium. Concert Pharmaceuticals Inc. has raised $110 million since its inception. The company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including HIV/AIDS, and renal disease, among others. USPTO granted Concert Pharmaceutical s first patents in 2009. Some of the company s investors include Brookside Capital Partners Fund, TVM Capital, Three Arch Partners, Fidelity Investments, Skyline Ventures, Flagship Ventures, Adage Capital Management and New Leaf Venture Partners.